ORKA General Counsel Paul T Quinlan Sells $707K of Stock

Oruka Therapeutics, Inc. General Counsel Paul T Quinlan sold 9,000 shares on October 20, 2026, according to a Form 4 filed with the Securities and Exchange Commission.

ORKA Oruka Therapeutics, Inc.

$74.48 ▲ +163.46% year to date

1M 3M YTD

Daily close · Oct 19, 2026

Inside Paul T Quinlan's Oruka Therapeutics Trade

The transaction was executed at an average price of $78.53, bringing the total value of the sale to roughly $706,734.90. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan. Following the completion of the trade, Quinlan holds 29,995 shares of the company, cutting his direct stake by about 23.08%.

Other Institutional Activity in Oruka Therapeutics

Venrock Adviser, LLC held 4,148,428 shares valued at about $328,099,155 without changing its position. Fairmount Funds Management LLC kept its holdings steady at 3,705,262 shares worth roughly $293,049,158. RTW Investments LP grew its holdings by 1,080,920 shares, ending with 3,139,030 shares worth about $248,265,871. Paradigm Biocapital Advisors LP reduced its stake by 175,887 shares, leaving it with 2,144,526 shares valued at roughly $169,610,553. Deep Track Capital, Lp trimmed its position by 108,221 shares to finish with 1,926,000 shares worth about $152,327,332.

Oruka Therapeutics, Inc. Stock Up 6.2%

The shares recently traded around $79.09, which puts the stock down about 14.1% from its 50-day moving average of $92.09 and up roughly 18.9% compared to its 200-day moving average of $66.54. The equity sits roughly 31.5% below its 52-week high of $115.52.

Recent Earnings

The biopharmaceutical developer reported a trailing-twelve-month loss with earnings per share at -$2.04 and a return on equity of -18.2%. The next financial update is scheduled for November 11, 2026.

Insider Buying and Selling at Oruka Therapeutics, Inc.

Chief Executive Officer Lawrence Otto Klein sold 1,729 shares at $69.69 on June 15, 2026, for a value of $120,494.01. General Counsel Paul T Quinlan previously sold 10,000 shares at $93.64 on September 21, 2026, in a planned trade worth $936,417. Senior Vice President of Finance Arjun Agarwal sold 9,999 shares at $80.60 on October 12, 2026, valued at $805,888.40 under a pre-arranged plan. Chief Medical Officer Joana Goncalves sold 7,000 shares at $74.81 on October 15, 2026, for $523,647.60 through a Rule 10b5-1 schedule.

Analysts Set New Price Targets

Guggenheim reiterated its Buy rating with a $200.00 target on August 11, 2026. HC Wainwright & Co. kept a Buy rating and a $120.00 target on September 3, 2026, and repeated that stance on September 24, 2026. Wedbush reaffirmed an Outperform rating with a $165.00 target on September 24, 2026. BTIG reiterated a Buy rating with a $151.00 target on October 19, 2026. Wall Street analysts hold a consensus strong buy recommendation on the stock.

About Oruka Therapeutics

Oruka Therapeutics is a clinical-stage biotech firm based in Menlo Park, California, working on monoclonal antibody therapies for plaque psoriasis and other immune-mediated conditions. Its pipeline includes candidates targeting the interleukin-23 and interleukin-17 pathways. Executive transactions draw close attention from market participants tracking insider sentiment.

Bottom Line

Participants will monitor the upcoming earnings report on November 11, 2026, for progress on clinical programs. Insider sales executed under pre-arranged schedules reflect planned liquidity moves rather than discretionary timing.